Connect with others who understand.

  • Learn from expert-reviewed resources
  • Real advice from people who’ve been there
  • People who understand what you’re going through
Sign up Log in
Personal Assistant What is This Site Help Center Crisis
Powered By

Top 4 search results for "Tabrecta" in Resources. To see all results and access other features, sign up for free.

Posts
Resources
Q&A
People
Groups
Treatments
Lung Cancer Treatment Options
... Capmatinib (Tabrecta) directly blocks the function of MET proteins. Tabrecta can be used to treat metastatic NSCLC if tumors have changes in the MET gene. ...
Lung Cancer Treatment Options
... Capmatinib (Tabrecta) directly blocks the function of MET proteins. Tabrecta can be used to treat metastatic NSCLC if tumors have changes in the MET gene. ...
NSCLC Targeted Therapy: 8 Facts
... Rozlytrek) Lorlatinib Repotrectinib (Augtyro) Taletrectinib (Ibtrozi) BRAF inhibitors Dabrafenib (Tafinlar) Encorafenib (Braftovi) Vemurafenib (Zelboraf) MEK inhibitors Binimetinib (Mektovi) Trametinib (Mekinist) RET inhibitors Cabozantinib (Cometriq, Cabometyx) Pralsetinib (Gavreto) Selpercatinib (Retevmo) MET inhibitors Capmatinib (Tabrecta ...
NSCLC Targeted Therapy: 8 Facts
... Rozlytrek) Lorlatinib Repotrectinib (Augtyro) Taletrectinib (Ibtrozi) BRAF inhibitors Dabrafenib (Tafinlar) Encorafenib (Braftovi) Vemurafenib (Zelboraf) MEK inhibitors Binimetinib (Mektovi) Trametinib (Mekinist) RET inhibitors Cabozantinib (Cometriq, Cabometyx) Pralsetinib (Gavreto) Selpercatinib (Retevmo) MET inhibitors Capmatinib (Tabrecta ...
Biomarkers for Lung Cancer: 12 Things To Know
... These treatments include: Capmatinib (Tabrecta) Telisotuzumab vedotin (Emrelis) Tepotinib (Tepmetko) 7. KRAS G12C Mutations Have Two Approved Targeted DrugsKRAS G12C is a biomarker seen in about 13 percent of advanced non-small cell lung cancers. ...
Biomarkers for Lung Cancer: 12 Things To Know
... These treatments include: Capmatinib (Tabrecta) Telisotuzumab vedotin (Emrelis) Tepotinib (Tepmetko) 7. KRAS G12C Mutations Have Two Approved Targeted DrugsKRAS G12C is a biomarker seen in about 13 percent of advanced non-small cell lung cancers. ...
NSCLC Treatment Options: First-Line Treatments and Beyond
... inhibitors, such as ceritinib (Zykadia), crizotinib (Xalkori), entrectinib (Rozlytrek), repotrectinib (Augtyro), and taletrectinib (Ibtrozi) BRAF inhibitors, such as dabrafenib (Tafinlar), encorafenib (Braftovi), and vemurafenib (Zelboraf) RET inhibitors, such as pralsetinib (Gavreto) and selpercatinib (Retevmo) MET inhibitors, such as capmatinib (Tabrecta ...
NSCLC Treatment Options: First-Line Treatments and Beyond
... inhibitors, such as ceritinib (Zykadia), crizotinib (Xalkori), entrectinib (Rozlytrek), repotrectinib (Augtyro), and taletrectinib (Ibtrozi) BRAF inhibitors, such as dabrafenib (Tafinlar), encorafenib (Braftovi), and vemurafenib (Zelboraf) RET inhibitors, such as pralsetinib (Gavreto) and selpercatinib (Retevmo) MET inhibitors, such as capmatinib (Tabrecta ...